Akums Drugs and Pharmaceuticals Limited (AKUMS) Price & Analysis

Compare

4 Followers

AKUMS Stock Chart & Stats

₹420.10

₹13.30(2.17%)

At close: Jan 08 4:00 PM EST

₹420.10

₹13.30(2.17%)

Day’s Range― - ―

52-Week Range₹407.40 - ₹620.00

Previous CloseN/A

Volume56.90K

Average Volume (3M)11.50K

Market Cap

₹76.97B

Enterprise Value₹70.61B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)23.4

Beta1.53

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.33

Shares Outstanding157,393,980

10 Day Avg. Volume12,021

30 Day Avg. Volume11,497

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.32

Price to Sales (P/S)1.74

P/FCF Ratio36.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹680.00

Price Target Upside61.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet DeleveragingThe steep reduction in leverage materially strengthens financial flexibility, lowers interest burden and increases capacity for capital allocation to R&D, capacity expansion or acquisitions. This durability improves resilience to industry shocks and supports strategic investment over the next 2-6 months.

Strong Cash GenerationConsistent operating cash flow and positive free cash flow growth indicate efficient cash conversion and internal funding capacity. Robust cash generation supports sustained capex, working capital needs and potential shareholder returns without reliance on fresh debt, a durable fundamental strength.

Improved Revenue And MarginsSustained revenue growth and meaningful expansion in gross and net margins suggest strengthened pricing, cost controls or favorable product mix. Improved profitability underpins reinvestment in products and distribution and enhances long-term competitiveness in generics and formulations.

Bears Say

Falling EBIT MarginA declining EBIT margin signals rising operating costs or lower operating leverage even as gross margins improved. If persistent, this erodes operating profitability and limits the company’s ability to convert top-line gains into sustainable operating cash flow and reinvestment.

Slight Decline In Operating Cash FlowWhile cash generation remains positive, the drop in OCF may reflect working capital build or collection pressures. Continued OCF weakness would reduce margins for discretionary spending and increase sensitivity to demand fluctuations, weakening financial resilience over months ahead.

Exposure To Generics Market PressureOperating in the highly competitive generics and contract manufacturing segment risks pricing erosion, margin compression and client concentration. Without clear product differentiation or pipeline advances, structural industry pressure could constrain revenue and margin sustainability.

Akums Drugs and Pharmaceuticals Limited News

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an announcement. Akums Drugs and Pharmaceuticals Limited has...

2M ago

AKUMS

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has shared an announcement. Akums Drugs and Pharmaceuticals Limited has...

4M ago

AKUMS

Akums Drugs Expands with New Subsidiary in Malta

The latest update is out from Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ). Akums Drugs and Pharmaceuticals...

4M ago

AKUMS

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an update. Akums Drugs and Pharmaceuticals Limited has...

4M ago

AKUMS

AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?

Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹407.40 and its highest was ₹620.00 in the past 12 months.

What is Akums Drugs and Pharmaceuticals Limited’s market cap?

Akums Drugs and Pharmaceuticals Limited’s market cap is ₹76.97B.

When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?

Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Jun 01, 2026 which is in 98 days.

How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?

Akums Drugs and Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹4.332 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.332.

Is Akums Drugs and Pharmaceuticals Limited overvalued?

According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.

What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?

Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?

Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.

What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?

Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.332 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.789%.

Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:AKUMS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited (AKUMS) is a leading Indian pharmaceutical manufacturer and exporter, specializing in the production of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Established in 2004, the company primarily operates in the sectors of prescription medicines, over-the-counter (OTC) products, and nutraceuticals. AKUMS is known for its commitment to quality and innovation, offering a diverse portfolio that includes formulations across various therapeutic segments such as cardiology, gynecology, and dermatology.

Akums Drugs and Pharmaceuticals Limited (AKUMS) Earnings & Revenues

Historic Earnings Reports

AKUMS Stock 12 Month Forecast

Average Price Target

₹680.00

▲(61.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"423":"₹423","552":"₹552","681":"₹681","487.5":"₹487.5","616.5":"₹616.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹680.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[423,487.5,552,616.5,681],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,456.15384615384613,474.8076923076923,493.46153846153845,512.1153846153846,530.7692307692307,549.4230769230769,568.0769230769231,586.7307692307693,605.3846153846154,624.0384615384615,642.6923076923076,661.3461538461538,{"y":680,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,456.15384615384613,474.8076923076923,493.46153846153845,512.1153846153846,530.7692307692307,549.4230769230769,568.0769230769231,586.7307692307693,605.3846153846154,624.0384615384615,642.6923076923076,661.3461538461538,{"y":680,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,456.15384615384613,474.8076923076923,493.46153846153845,512.1153846153846,530.7692307692307,549.4230769230769,568.0769230769231,586.7307692307693,605.3846153846154,624.0384615384615,642.6923076923076,661.3461538461538,{"y":680,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":566,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":523.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":568.2,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":574.7,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":514.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":466.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":451.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.25,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":424.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":446.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >